Internal Medicine, Gastroenterology · Lawrenceville, GA
NPI
1477581999
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
721 Wellness Way, Suite100
Lawrenceville, GA, 30046
Phone (770) 995-7989
Groups this clinician bills Medicare through
Medicare paid, 2024
$77K
723 services
Medicare patients, 2024
379
Average age 74
Drug cost, 2024
$721K
2,005 prescriptions
Company payments, 2025
$1,136
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jae W Nam was code 43239 (upper gi endoscopy), 157 times for 154 patients. In total Jae W Nam billed 723 services in 33 codes, and Medicare paid $77K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-01-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 43239 Upper GI Endoscopy | Facility | 157 | 154 | $84.34 | $13K |
| 99213 Office E&M - Established | Office | 130 | 108 | $59.66 | $7,756 |
| 45385 Colonoscopy - Lesion Removal | Facility | 70 | 69 | $201.88 | $14K |
| 99214 Office E&M - Established | Office | 64 | 59 | $89.68 | $5,740 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 46 | 46 | $179.64 | $8,263 |
| 99204 Office E&M - New | Office | 43 | 43 | $105.02 | $4,516 |
| 99203 Office E&M - New | Office | 42 | 42 | $69.03 | $2,899 |
| 45380 Lower GI Endoscopy - Other | Facility | 37 | 37 | $149.53 | $5,533 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 20 | 20 | $173.18 | $3,464 |
| 99212 Office E&M - Established | Office | 14 | 14 | $38.74 | $542 |
| 45378 Lower GI Endoscopy - Other | Facility | 12 | 12 | $133.18 | $1,598 |
| 99221 Hospital E&M - Initial | Facility | 11 | 11 | $64.66 | $711 |
By year: 2022 $92K for 837 services; 2023 $86K for 755 services; 2024 $77K for 723 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jae W Nam prescribed most often to Medicare patients was Omeprazole, with 590 prescriptions and refills. In total Jae W Nam wrote 2,005 Medicare prescriptions that cost $721K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 590 | 1,644 | 298 | $5,497 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 402 | 402 | 400 | $64K |
| Pantoprazole Sodium Generic | 212 | 561 | 88 | $2,184 |
| Clenpiq Sod Picosulf/Mag Ox/Citric Ac | 80 | 80 | 80 | $14K |
| Linzess Linaclotide | 73 | 166 | 38 | $87K |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 50 | 50 | 50 | $932 |
| Creon Lipase/Protease/Amylase | 46 | 53 | Under 11 | $98K |
| Amoxicillin Generic | 43 | 43 | 43 | $163 |
| Clarithromycin Generic | 41 | 41 | 41 | $886 |
| Mesalamine Generic | 34 | 70 | Under 11 | $23K |
| Ursodiol Generic | 33 | 49 | Under 11 | $4,886 |
| Famotidine Generic | 32 | 73 | 13 | $476 |
| Sucralfate Generic | 31 | 41 | 17 | $1,128 |
| Ondansetron Odt Ondansetron | 29 | 29 | 16 | $324 |
| Lubiprostone Generic | 26 | 41 | 15 | $3,515 |
Brand drugs: 714 claims; generic drugs: 1,291 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jae W Nam $1,136 ($1,136 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $257.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 19 | $257 |
| Janssen Biotech, Inc. JNJ | 11 | $136 |
| Genzyme Corporation SNY | 4 | $103 |
| Madrigal Pharmaceuticals MDGL | 5 | $99.6 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $89.03 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $88.16 |
| Gilead Sciences, Inc. GILD | 4 | $72.93 |
| Ardelyx, Inc. ARDX | 2 | $48.86 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $45.86 |
| Phathom Pharmaceuticals, Inc. PHAT | 4 | $40.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.